colorectal cancer
Conditions
Interventions
1)Capecitabine at a dose of 2,000mg/m2/day orally in 2 divided doses for 2weeks on and 1week rest 2) tri-Weekly oxaliplatin at a dose of 130mg/m2 intravenously 3) tri-weekly bevacizumab at a dose
Sponsors
Nagoya City University Gastrointestinal Surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 20 years or older 2.Histologically confirmed colorectal cancer 3.With target lesion by RECIST ver.1.1 4.Unrecetable recurrent or metastatic colorectal cancer.Not be administered any therapies except radio therapy when primary disease or primary recurrence and not be administered any therapy for reccurent tumor 5.Patients who can take food orally 6. Patients who will be administered the therapy of XELOX+Bevacizumab 7.Written IC
Exclusion criteria
Exclusion criteria: 1. Prior or synchronous invasive malignancy unless disease free for a minimum of 5 years 2.Previous history of severe drug-induced allergy caused by capecitabine 3.Be Administered or less than 7 days finished administration Compound Drug of tegafur,gimeracil and oteracil potassium 4.Severe kidney trouble 5.Previous history of severe drug-induced allergy caused by oxaliplatin 6. Neuropathy or sensory dysfunction 7.Previous history of severe drug-induced allergy caused by bevacizumab 8.Pregnant women who are capable of pregnancy or intend to get pregnant 9.Patients judged inappropriate for this study by the physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency and Degree of Hand-foot symdrome(HFS),Neuropathy and Vascular disorders | — |
Secondary
| Measure | Time frame |
|---|---|
| Time To Failure, Disease Free Survival, Overall Survival, Overall Response Rate, Frequency and Degree of Adverse Events Except HFS,Neuropathy and Vascular disorders. Resection Rate of Liver Metastases, Rate of R0 Resection of Liver Metastases | — |
Countries
Japan
Contacts
Public ContactMikinori Sato, Masayasu Hara
Nagoya City University Gastrointestinal Surgery
Outcome results
None listed